Bullish
Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304
Beam Therapeutics (BEAM) is under investor focus after the FDA cleared its investigational new drug application for BEAM-304, an in vivo base editing ...